USA – Ride Wave Ventures, an angel investor, has made its first investment in American Gene Technologies, a clinical-stage biotechnology company working to cure HIV.

The investment by Ride Wave Ventures adds to the more than US$50 million in venture capital that American Gene Technologies has received thus far.

American Gene Technologies is a gene and cell therapeutics company with a proprietary lentiviral platform capable of broad applications.

It develops bio-safe lentivirus therapies to treat cancer, HIV/AIDS, and other chronic human disorders. The company’s mission is to leverage the power of gene and cell therapy to reduce human suffering from serious human diseases.

These capital inflows go directly toward the development of gene therapies for some of humanity’s most heinous diseases, such as HIV, cancer, and phenylketonuria (PKU).

Ride Wave Ventures invests in companies that it believes have the potential to generate venture-class returns.

Ride Wave seeks high-growth companies with “huge or growing total addressable markets,” particularly those with a product or service that alters people’s behavior and creates a new market or significantly expands an existing one.

This investment from Ride Wave Ventures is a welcome and significant vote of confidence in our future from a rising angel investor,” said American Gene Technologies Business Development Director Norman Rogers.

We’re excited and gratified that Ride Wave Ventures’ continual search for big-idea companies brought our work to its attention, and we appreciate the opportunity to collaborate and propel one another forward.”

American Gene Technologies, a clinical-stage biotechnology company working to cure HIV, has launched The Cure Chronicles, a video series featuring compelling HIV community conversations hosted by the company’s CEO Jeff Galvin.

With over 37 million people worldwide infected with HIV/AIDS, American Gene Technologies is working hard to find a cure.

The company is currently conducting a clinical trial for a single-infusion gene therapy (AGT103-T) to help people living with HIV return to a normal life.

We believe there is hope for a cure, but we know it will take everyone working together to make it a reality and permanently end the suffering of millions of people living with HIV today,” says Galvin.

 “That’s why we’ve launched this video series: to have thoughtful conversations with people living with HIV, advocates, medical experts, policy makers, and others who are working hard toward the shared goal of ending this devastating epidemic.”

With “The Cure Chronicles,” American Gene Technologies wants to spotlight some of the many advocates and people in the HIV community who strive to keep hope alive and tip the odds toward success.

The Cure Chronicles can be found at: https://www.americangene.com/the-cure-chronicles/

Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE